Trader consensus implies an 88.5% probability against a new pandemic in 2026, driven by the absence of any novel pathogen achieving sustained human-to-human transmission at global scale, according to ongoing WHO and CDC surveillance data through mid-April. Recent developments, including the March emergence of SARS-CoV-2 variant BA.3.2 ("Cicada") in over 20 countries with detections in U.S. wastewater, have not triggered public health emergency thresholds, as cases align with endemic COVID-19 patterns rather than pandemic escalation. Sporadic H5N1 avian influenza human infections persist without clusters indicating adaptation, while U.S. measles outbreaks exceed 1,700 cases but remain vaccine-preventable and localized. Key upcoming catalysts include WHO genomic monitoring updates and influenza season wrap-up reports, which could shift odds if unexpected transmission surges occur.